Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    21969517 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Pilot Study of ODSH in Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: PGX-ODSH-2013-AML-1
2 Unknown  Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: gemcitabine
3 Completed Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: FOLFIRINOX;   Genetic: Immunohistochemistry (IHC) Analysis;   Drug: Metformin;   Drug: mFOLFIRI
4 Completed Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel);   Drug: Gemcitabine;   Drug: ODSH ( 2-O, 3-O Desulfated Heparin);   Drug: Abraxane ( nab-paclitaxel)
5 Completed
Has Results
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: Albumin-bound paclitaxel

Indicates status has not been verified in more than two years